Practice Intervention Targeting IV Opioids May Cut Exposure

Share this content:
Practice Intervention Targeting IV Opioids May Cut Exposure
Practice Intervention Targeting IV Opioids May Cut Exposure

MONDAY, May 13, 2018 (HealthDay News) -- An intervention targeting the use of intravenous opioids may reduce opioid exposure, according to a study published online May 14 in JAMA Internal Medicine.

Adam L. Ackerman, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues conducted a pilot study involving attending physicians, nurse practitioners, and physician assistants who prescribed drugs. Opioid use was compared between a six-month control period and three months following education for prescribers on opioid administration routes, focusing on awareness of the subcutaneous routes.

The researchers observed an 84 percent reduction in intravenous opioid doses and a 55 percent reduction in doses of all parenteral opioids. In addition, there was a 49 percent decrease in the mean daily parenteral opioid exposure. There was a 57 percent decrease in the daily rate of patients administered any parenteral opioid. Reductions were seen in doses of opioids given by oral or parenteral route (23 percent) and mean daily overall opioid exposure (31 percent). For hospital days one through three, there were no significant differences in mean reported pain score for patients receiving opioid therapy post-intervention versus pre-intervention; there was significant improvement in the intervention group on days four and five.

"An intervention targeting the use of intravenous opioids may be associated with reduced opioid exposure while providing effective pain control to hospitalized adults," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »